BioNotebook: Vivus's 'disappointing' Qsymia sales, Celladon/Servier, Ardelyx/Sanofi, Thesan, Arrowhead
This article was originally published in Scrip
Executive Summary
Vivus's Qsymia sales disappoint again; Celladon rises on Servier option; Ardelyx adds Sanofi partnership; Secretive Thesan raises $49m; and Arrowhead closes $120m offering.